The NAGOMI™ platform
A platform for noninvasive precision dosing.
NAGOMI™ combines monitorable therapeutic carriers, a compact light-enabled wearable interface, and optical feedback to help transform hard-to-dose medicines into controllable therapies.
The dosing problem
Many powerful therapies are limited by how hard they are to dose.
Many powerful therapies are limited not by molecular potency, but by the difficulty of controlling exposure over time. Narrow therapeutic windows, PK variability, toxicity, and burdensome administration make dosing hard for patients and clinicians.
Narrow therapeutic windows
Small changes in exposure can create large changes in efficacy or toxicity.
PK variability
Patients respond differently based on metabolism, disease state, and clinical context.
Peak-related toxicity
High systemic peaks can limit how aggressively potent therapies can be used.
Frequent injections or infusions
Many therapies rely on repeated administration, infusion pumps, or clinical supervision.
Burdensome monitoring
Dosing often depends on delayed measurements, clinic visits, or trial-and-error adjustments.
Dosing uncertainty
Fixed dosing can make it difficult to keep patients in the desired therapeutic range.
The NAGOMI™ approach
Three integrated components. One therapeutic interface.
Monitorable Therapeutic Carriers
Proprietary carriers designed to encapsulate therapeutic payloads and provide optical feedback related to carrier state.
Light-Enabled Wearable Interface
A compact wearable device enables noninvasive, on-demand drug dosing without indwelling hardware.
Optical Feedback
Real-time optical readout supports feedback-informed dosing and closes the loop between activation and response.
How it works
Encapsulate. Activate. Monitor.
01Encapsulate
A therapy is formulated into monitorable carriers designed for controlled activation.
02Activate
A compact wearable device delivers a noninvasive light stimulus to trigger nonivasive drug release.
03Monitor
Optical feedback provides information about carrier response, enabling precise therapeutic control.
Why it matters
Not just controlled release. Controlled release with feedback.
Better therapeutic control
Designed to help manage exposure over time, not just at the moment of administration.
Longer exposure. Fewer doses.
Designed to extend therapeutic half-life for compatible drugs, reducing repeat administrations and treatment burden.
Feedback-informed dosing
Monitoring is built into the platform concept, not bolted on afterward.
Pharma product differentiation
A pathway to more controllable, patient-friendly versions of established or emerging therapies.
Platform-compatible strategy
Designed to apply across multiple therapeutic areas and drug classes.
High-need use cases
Focused on drugs limited by toxicity, PK variability, narrow windows, or administration burden.
Explore whether NAGOMI™ fits your therapy.
We're engaging pharmaceutical, biotech, government, and research partners around precision-dosing collaborations.
Partner with us